Traders Recap on Worth Watching Stocks: Weatherford International Plc (NYSE:WFT), U.S. Bancorp (NYSE:USB), AstraZeneca plc (ADR) (NYSE:AZN)

On Wednesday, Shares of Weatherford International Plc (NYSE:WFT), added 6.93% and closed at $5.71 in the last trading session. The last trading range of the stock ranges between $5.41 and $5.81. Weatherford International plc (WFT) declares that, as of September 30, 2016, Dr. Mario Ruscev has officially begun to serve as Executive Vice President, President  Product Lines and Chief Technology Officer for Weatherford International plc, reporting directly to Bernard J. Duroc-Danner, Chairman of the Board, President and Chief Executive Officer.

Dr. Ruscev commented, “I look forward to leading Weatherford’s operational team and strengthening the Company’s integrated product line strategy. With a firm commitment to delivering the highest service quality and reliability to our clients, we will build on our technological capabilities, implementing and further advancing our industrial innovations.”

U.S. Bancorp (NYSE:USB), jumped 1.87% and closed at $43.65 in the last trading session. The last trading range of the stock ranges between $43.02 and $43.81. The company’s Market capitalization is $75.04 Billion with the total Outstanding Shares of 1.72 Billion. U.S. Bancorp recently declared the redemption on October 14, 2016, of all of its outstanding 2.20% Medium-Term Notes, Series T (Senior), due November 15, 2016 (CUSIP No. 91159HHB9). The redemption price will be equal to $1,000 per $1,000 original principal amount, plus any accrued and unpaid interest to, but apart from, the redemption date of October 14, 2016.

Payment of the redemption price will be made through the facilities of The Depository Trust Company.

Minneapolis-based U.S. Bancorp (USB), with $438 billion in assets as of June 30, 2016, is the parent company of U.S. Bank National Association, the fifth leading commercial bank in the United States. The company operates 3,122 banking offices in 25 states and 4,923 ATMs and provides a comprehensive line of banking, investment, mortgage, trust and payment services products to consumers, businesses and institutions. Visit U.S. Bancorp on the web.

AstraZeneca plc (ADR) (NYSE:AZN), gained 0.09% and closed at $32.60 in the last trading session. The last trading range of the stock ranges between $32.51 and $32.76. During the 52-week trading session the minimum price at which share price traded, registered at $26.97 and reached to max level of $35.04. AstraZeneca PLC engages in the discovery, development, and commercialization of prescription medicines for the treatment of respiratory, inflammation, autoimmune, cardiovascular, metabolic, oncology, infection, neuroscience, and gastrointestinal diseases worldwide. Its marketed products comprise Accolate, Bricanyl Respules, Bricanyl Turbuhaler, Daliresp, Duaklir Genuair, Eklira Genuair/Tudorza/Bretaris, Oxis Turbuhaler, Pulmicort Turbuhaler/Pulmicort Flexhaler, Pulmicort Respules, Rhinocort, Symbicort pMDI, and Symbicort Turbuhaler for respiratory, inflammation, and autoimmunity diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor2, Plendil, Seloken/Toprol-XL, Tenormin3, and Zestril4 for cardiovascular disease; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Symlin, Xigduo, and Xigduo XR for metabolic disease. The company’s marketed products also include Arimidex, Faslodex, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex, in addition to Casodex, Cosudex for oncology disease; Fluenz/FluMist, Fluenz Tetra/FluMist Quadrivalent1, Merrem/Meronem2, Synagis3, and Zinforo4 for infection disease; Diprivan, EMLA, Movantik/Moventig, Naropin, Seroquel IR, Seroquel XR, Vimovo1, Xylocaine, and Zomig for neuroscience disease; and Losec/Prilosec and Nexium for gastrointestinal disease. It mainly serves primary care and specialty care physicians through distributors and local representative offices. The company’s pipeline includes 146 projects, of which 125 are in the clinical phase of development. It has partnershipagreements with Celgene Corporation; Immunocore Limited; Eli Lilly and Company; Heptares Ltd.; Foundation Medicine, Inc., French National Institute of Health and Medical Research (Inserm); and FibroGen and Astellas.

Leave a Reply

Your email address will not be published. Required fields are marked *